Investment Highlights

Photocure holds a strong position in the field of bladder cancer with solid growth plans and ambition to expand its footprint.

A commercial-stage company focused on bladder cancer

Hexvix®/Cysview® is a product for the detection of bladder cancer:

  • USD 30M global in market sales.
  • Specialist salesforce established in the U.S. and European region and additional emerging operations in other high-value territories through our partners, Juno Pharmaceuticals (Australia/New Zealand), and BioSyent Pharma (Canada).

Value-building opportunity

  • Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories.
  • FDA approval of Cysview® for use with flexible cystoscope.
  • Clarity on reimbursement for Cysview® in the U.S.
  • Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure.